ArticleMediterranean journal of hematology and infectious diseases2025

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.

Katia Paciaroni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.